Outlook 2024
Annual Industry Ranking And Forecast
World View
Approximately 25% of active drug development originates from China, with a focus on biologics, cell therapies, and cancer R&D. Despite strong interest from multinational pharmaceutical companies, a financing crunch in the startup space is impacting China's biotech sector.
Latin America And Caribbean Move Towards Creating A New Regional Regulator
Industry support for a new regional regulator for Latin America and the Caribbean is cautious and experts warn that it could harm competitiveness of the region.
The Growing Pains Of Chinese Biotech
The emergence of China from API manufacturer to an innovation leader, fuelled by domestic investments and home-grown talent, has been one of the most remarkable trends of the last decade.
How Korea Can Avoid Pitfalls Of Over-Reliance On Out-Licensing
An over-reliance on out-licensing as a business model may restrict the healthy growth of South Korean biopharma firms over the longer term, a Citeline executive told a recent symposium in Seoul.
How The UK Is Reinvigorating Its Clinical Trials Industry
In the year since the Association of the British Pharmaceutical Industry raised the alarm about drastically dwindling clinical trial recruitment numbers in the UK, the country has taken a number of steps to try to turn things around.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.